Is brigatinib/brigatinib an imported drug or a domestic drug?

Brigatinib/Brigatinib (Brigatinib) is an original drug developed by an overseas company. It has been approved in the Chinese market and has been included in the Class B medical insurance directory. After the original drug of brigatinib was launched in China, it has been widely used, especially for patients with non-small cell lung cancer (NSCLC) with ALK gene mutations. The approval of this drug provides a new treatment option for patients with advanced lung cancer in China.

In China, brigatinib can be found in a variety of specifications on the market, including30 mg × 14 tablets in 2 plates, 90 mg × 7 tablets, 180 mg × 7 tablets in 4 plates, etc. Whether it is clinical treatment or home treatment, patients can choose the specifications that suit them according to the guidance of their doctor. Currently, brigatinib is an imported drug that enters the Chinese market through import channels. Its price is relatively high, but its therapeutic effect has been widely recognized in clinical practice.

Although brigatinib has been launched in China and has been reimbursed by medical insurance, there is currently no domestic brigatinib drug on the domestic market. Domestic generic drugs have not officially entered the market, which means that patients can only obtain treatment with the drug through imported drugs. Imported drugs are usually priced higher, but as drugs are gradually included in medical insurance, some patients can reduce their financial burden through medical insurance reimbursement.

It should be noted that since brigatinib is an imported drug, its price may be affected by exchange rate fluctuations and import tariffs, which may also result in its price being higher compared to domestically produced drugs. However, as competition in the international market intensifies, generic versions of brigatinib may appear in the future, driving prices down further.

Generally speaking, brigatinib is currently an imported drug, and there are no domestic generic drugs on the market yet. This situation makes the price of drugs higher, and patients need to make choices based on medical insurance policies and economic conditions when using them.

Reference materials:https://www.alunbrig.com/